Previous 10 | Next 10 |
2024-01-26 12:32:20 ET Gainers: Corbus Pharmaceuticals Holdings ( CRBP ) +300% . Aclarion ( ACON ) +66% . Panbela Therapeutics ( PBLA ) +36% . Inspire Veterinary Partners ( IVP ) +36% . Rail Vision Ltd ( RVSN ) +34% . Appfoli...
2024-01-26 08:32:05 ET Losers: Aclarion ( ACON ) 119% . Panbela Therapeutics ( PBLA ) 59% . Processa Pharmaceuticals ( PCSA ) 29% . Corbus Pharmaceuticals Holdings ( CRBP ) 23% . as targeting antibody drug conjugate demonstrates encouragin...
Interim Data Analysis Anticipated in Mid-2024 Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent u...
2024-01-23 09:59:59 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-23 08:25:53 ET More on Pre-market losers & stocks. Mesoblast Has Major Hurdles Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast rises after cell therapy gets FDA rare pediatric disease designation MSP Recovery stock tu...
2024-01-22 12:31:12 ET Gainers: Sagimet Biosciences ( SGMT ) +106% . Rail Vision Ltd ( RVSN ) +51% . Digital World Acquisition Corp ( DWAC ) +49% . Bullfrog AI Holdings ( BFRG ) +38% . CXApp ( CXAI ) +34% . Phunware ( PHUN ...
2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...
2024-01-18 10:00:02 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare had the largest net buying in five months - Goldman Health stocks to watch ...
2024-01-18 09:18:57 ET More on Panbela Therapeutics Panbela Therapeutics, Inc. (PBLA) Q3 2023 Earnings Call Transcript Panbela announces 1-for-20 reverse stock split Panbela Therapeutics announces exercise of existing warrants Seeking Alpha’s Quant Rat...
MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces the publication of clinical data from studies of CPP-1...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...